LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Unique Dye-Based Tests to Revolutionize Early-Detection Pancreatic Cancer Diagnostics

By LabMedica International staff writers
Posted on 17 Mar 2023
Print article
Image: New diagnostic tests could accurately detect and pre-empt risks of debilitating diseases (Photo courtesy of Amplified Sciences)
Image: New diagnostic tests could accurately detect and pre-empt risks of debilitating diseases (Photo courtesy of Amplified Sciences)

Pancreatic cancer is the third deadliest cancer, with 74 out of every 100 patients succumbing to it within a year of diagnosis as it is often detected too late to be treated effectively. Now, that could change with the development of new tests that use dyes to detect the possibility of malignancy in fluid extracted from pancreatic cysts. When appropriately evaluated, these cysts can provide a means of detecting pancreatic cancer at an earlier stage.

Amplified Sciences Inc. (West Lafayette, IN, USA) is currently developing a range of diagnostic tests for early cancer detection, specifically designed to identify the likelihood of cancer development. Not only can these tests confirm the absence of malignancy in patients with cysts, but they could also reduce the number of inaccurate diagnoses and alleviate patient concerns. The company has successfully conducted clinical trials on its pancreatic cancer test which is now poised for translation to a clinical lab and to enter the regulatory process.

While the future for these early cancer detection tests appears promising, there are also practical challenges that must be addressed. In addition to laboratory-related obstacles, the successful regulatory approval of these tests could necessitate the training of more gastroenterologists to collect fluid from pancreatic cysts, a procedure that is not usually included in standard medical school training for all gastroenterologists.

“Earlier detection, followed by surgical removal, has a much better prognosis,” said Diana Caldwell, Amplified Sciences’ chief executive officer. “We also hope that, with early detection, scientists can identify interventions that can impact early stage pancreatic cancer. That’s a principle of cancer treatment – the earlier you get it, the more likely pharmaceuticals and other therapies are able to resolve it.”

Related Links:
Amplified Sciences Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more